Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | -11.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | -11.46% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
Veracyte's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, gaining 1.22%, likely due to market optimism about the company's long-term growth potential. The lack of revenue data and guidance may leave investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CATALYST PHARMACEUTI
Mar 16, 2015